A genome-wide association study of acenocoumarol maintenance dosage
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Several genome-wide association studies have been performed on warfarin. For acenocoumarol, the most frequently used coumarin in many countries worldwide, pharmacodynamic influences are expected to be comparable. Pharmacokinetics however might differ. We aimed to confirm known or identify new genetic variants contributing to interindividual variation on stabilized acenocoumarol dosage by a GWAS. The index population consisted of 1451 Caucasian subjects from the Rotterdam study and results were replicated in 287 subjects from the Rotterdam study extended cohort. Both cohorts were genotyped on the Illumina 550K Human Map SNP array. From polymorphisms tested for association with acenocoumarol dosage, 35 single nucleotide polymorphisms (SNPs) on chromosome 16 and 18 SNPs on chromosome 10 reached genome-wide significance. The SNP with the lowest P-value was rs10871454 on chromosome 16 linked to SNPs within the vitamin K epoxide reductase complex subunit 1 (VKORC1) (P = 2.0 x 10(-123)). The lowest P-value on chromosome 10 was obtained by rs4086116 within cytochrome P450 2C9 (CYP2C9) (P = 3.3 x 10(-24)). After adjustment for these SNPs, the rs2108622 polymorphism within cytochrome P450 4F2 (CYP4F2) gene on chromosome 19 reached genome-wide significance (P = 2.0 x 10(-8)). On chromosome 10, we further identified genetic variation in the cytochrome P450 2C18 (CYP2C18) gene contributing to variance of acenocoumarol dosage. Thus we confirmed earlier findings that acenocoumarol dosage mainly depends on polymorphisms in the VKORC1 and CYP2C9 genes. Besides age, gender, body mass index and target INR, one polymorphism within each of the VKORC1, CYP2C9, CYP4F2 and CYP2C18 genes could explain 48.8% of acenocoumarol dosage variation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pe'er, I., Yelensky, R., Altshuler, D., & Daly, M. J. (2008) · Genetic Epidemiology · doi:10.1002/gepi.20303 · Cited by 783
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Cooper, G. M., Johnson, J. A., Langaee, T. Y., Feng, H., Stanaway, I. B., Schwarz, U. I., Ritchie, M. D., Stein, C. M., Roden, D. M., Smith, J. D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-134247 · Cited by 481
Research works printed but not linked: 30
- Montes, 2006, The c.-1639G>A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients, Br. J. Haematol., 133, 183, 10.1111/j.1365-2141.2006.06007.x · doi:10.1111/j.1365-2141.2006.06007.x
- Schalekamp, 2006, VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation, Clin. Pharmacol. Ther., 80, 13, 10.1016/j.clpt.2006.04.006 · DOI
- Aquilante, 2006, Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements, Clin. Pharm. Therap., 79, 291, 10.1016/j.clpt.2005.11.011 · DOI · Paper page
- Carlquist, 2006, Genotypes of the cytochrome p450 isoform, CYP2C9 , and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study, J. Thromb. Thrombolysis, 22, 191, 10.1007/s11239-006-9030-7 · DOI · Paper page
- Crawford, 2007, Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing, Pharmacogenomics, 8, 487, 10.2217/14622416.8.5.487 · DOI
- D'Andrea, 2005, A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin, Blood, 105, 645, 10.1182/blood-2004-06-2111 · DOI · Paper page
- Geisen, 2005, VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation, Thromb. Haemost., 94, 773, 10.1160/TH05-04-0290 · DOI · Paper page
- Oldenburg, 2007, Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles, Thromb. Haemost., 98, 570, 10.1160/TH07-07-0454 · doi:10.1160/th07-07-0454
- Reitsma, 2005, A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk, PLoS Med., 2, e312, 10.1371/journal.pmed.0020312 · doi:10.1371/journal.pmed.0020312
- Sconce, 2005, The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen, Blood, 106, 2329, 10.1182/blood-2005-03-1108 · DOI · Paper page
- Li, 2008, Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy, Blood, 113, 3925, 10.1182/blood-2008-09-176859 · doi:10.1182/blood-2008-09-176859
- Wadelius, 2007, Association of warfarin dose with genes involved in its action and metabolism, Hum. Genet., 121, 23, 10.1007/s00439-006-0260-8 · DOI · Paper page
- Caldwell, 2008, CYP4F2 genetic variant alters required warfarin dose, Blood, 111, 4106, 10.1182/blood-2007-11-122010 · DOI · Paper page
- Borgiani, 2009, CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population, Pharmacogenomics, 10, 261, 10.2217/14622416.10.2.261 · DOI
- Bodin, 2005, Cytochrome P450 2C9 ( CYP2C9 ) and vitamin K epoxide reductase ( VKORC1 ) genotypes as determinants of acenocoumarol sensitivity, Blood, 106, 135, 10.1182/blood-2005-01-0341 · DOI · Paper page
- Spreafico, 2008, Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy, Fut. Med., 9, 1237
- Teichert, 2009, Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period, Clin. Pharmacol. Ther., 85, 379, 10.1038/clpt.2008.294 · DOI
- Markatos, 2008, VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients, Pharmacogenomics, 9, 1631, 10.2217/14622416.9.11.1631 · doi:10.2217/14622416.9.11.1631
- Verde, 2009, Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients, Thromb. Haemost., 101, 591, 10.1160/TH08-09-0578 · doi:10.1160/th08-09-0578
- Anderson, 2007, Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation, Circulation, 116, 2563, 10.1161/CIRCULATIONAHA.107.737312 · DOI · Paper page
- Caraco, 2007, CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study, Clin. Pharmacol. Ther., 83, 460, 10.1038/sj.clpt.6100316 · DOI · Paper page
- Ufer, 2005, Comparative pharmacokinetics of vitamin K antagonists, Clin. Pharmacokinet., 44, 1227, 10.2165/00003088-200544120-00003 · DOI
- Rieder, 2005, Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose, N. Engl. J. Med., 352, 2285, 10.1056/NEJMoa044503 · DOI · Paper page
- Sontag, 2002, Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism: novel mechanism of regulation of vitamin E status', J. Biol. Chem., 277, 25290, 10.1074/jbc.M201466200 · DOI · Paper page
- Hofman, 1991, Determinants of disease and disability in the elderly: the Rotterdam elderly study, Eur. J. Epidemiol., 7, 403, 10.1007/BF00145007 · DOI · Paper page
- Hofman, 2007, The Rotterdam Study: objectives and design update, Eur. J. Epidemiol., 22, 819, 10.1007/s10654-007-9199-x · DOI · Paper page
- Miller, 1988, A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acids Res., 16, 1215, 10.1093/nar/16.3.1215 · DOI · Paper page
- Visser, 2004, The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon, Pharmacogenetics, 14, 27, 10.1097/00008571-200401000-00003 · DOI
- Stolk, 2008, The RIZ Pro704 insertion-deletion polymorphism, bone mineral density and fracture risk: The Rotterdam study, Bone, 42, 286, 10.1016/j.bone.2007.10.008 · DOI
- Thijssen, 2000, Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes, Drug. Metabol. Dispos., 28, 1284, 10.1016/S0090-9556(24)15074-X · doi:10.1016/s0090-9556(24)15074-x
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“Interindividual dosage variation for the anticoagulants acenocoumarol (Teichert et al., 2009) and phenprocoumon (Teichert et al.”
BackgroundWang, L., McLeod, H. L., & Weinshilboum, R. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1010600 · Cited by 613
Roden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., & Van Driest, S. L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31276-0 · Cited by 427
The Rotterdam Study: 2014 objectives and design update
Hofman, A., Murad, S. D., van Duijn, C. M., Franco, O. H., Goedegebure, A., Arfan Ikram, M., Klaver, C. C. W., Nijsten, T. E. C., Peeters, R. P., Stricker, B. H. C., et al. (2013) · European Journal of Epidemiology · doi:10.1007/s10654-013-9866-z · Cited by 330
Self-citationDeelen, J., Beekman, M., Uh, H., Helmer, Q., Kuningas, M., Christiansen, L., Kremer, D., van der Breggen, R., Suchiman, H. E. D., Lakenberg, N., et al. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00705.x · Cited by 285
Self-citation
Metadata
- Authors
- Teichert, M., Eijgelsheim, M., Rivadeneira, F., Uitterlinden, A. G., van Schaik, R. H. N., Hofman, A., De Smet, P. A. G. M., van Gelder, T., Visser, L. E., & Stricker, B. H. C.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-07-04
- Volume
- 18
- Issue
- 19
- Pages
- 3758-3768
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2137669083
- Cited by
- 148
- References
- 2
- FWCI
- 16.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.